HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 1071-1083
DOI: 10.3350/cmh.2025.0145 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Vincent Wai-Sun Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Berberine, Ursodeoxycholic Acid, Fatty Liver. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HighTide Therapeutics, Inc..
Abstract (Originalsprache)
Background/Aims: Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus. The purpose of this assessment was to establish proof of concept in liver histologic improvement with HTD1801 treatment based on preclinical and clinical evidence.Methods: The efficacy of HTD1801 was evaluated in a preclinical MASH/dyslipidemia model (golden hamsters fed a high fat diet, eight/group) after six weeks of daily treatment. Additionally, in a secondary analysis of a Phase 2 clinical study, 100 patients with presumed MASH were evaluated by multiple noninvasive markers associated with MASH resolution and/or fibrosis improvement. These include magnetic resonance imaging proton density fat fraction (MRIPDFF; ≥30% LFC reduction), iron-corrected T1 (≥80 ms reduction), alanine aminotransferase (≥17 U/L reduction), weight loss (≥5% reduction), Fibrosis-4 index (shift to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
- Covenant Metabolic Specialists LLC., Westchester, FL, USA.
- HighTide Therapeutics, Inc., Rockville, MD, USA.
- Shenzhen HighTide Biopharmaceutical Ltd., Shenzhen, China.
- Velocity Clinical Research, Waco, TX, USA.
Förderung
- HighTide Therapeutics, Inc.
Zitieren
APA
Wong, V. W., Neff, G. W., Di Bisceglie, A. M., Bai, R., Cheng, J., Yu, M., Liberman, A., Liu, L., & Gunn, N. (2025). HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clinical and Molecular Hepatology, 31(3), 1071-1083. https://doi.org/10.3350/cmh.2025.0145
Vancouver
Wong VW, Neff GW, Di Bisceglie AM, Bai R, Cheng J, Yu M, et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clinical and Molecular Hepatology. 2025;31(3):1071-1083. doi:10.3350/cmh.2025.0145
BibTeX
@article{Wong2025,
author = {Wong, Vincent Wai-Sun and Neff, Guy W and Di Bisceglie, Adrian M and Bai, Ru and Cheng, Junwei and Yu, Meng and Liberman, Alexander and Liu, Liping and Gunn, Nadege},
title = {HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {3},
pages = {1071--1083},
doi = {10.3350/cmh.2025.0145}
}
EUVIMED